Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: A case-control study

Kaja Tikk, Disorn Sookthai, Renée T. Fortner, Theron Johnson, Sabina Rinaldi, Isabelle Romieu, Anne Tjønneland, Anja Olsen, Kim Overvad, Françoise Clavel-Chapelon, Laura Baglietto, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Giovanna Masala, Vittorio Krogh, Rosario Tumino, Fulvio Ricceri, Amalia MattielloAntonio Agudo, Virginia Menéndez, María José Sánchez, Pilar Amiano, Maria Dolores Chirlaque, Aurelio Barricarte, Hbas Bueno-de-Mesquita, Evelyn M. Monninkhof, N. Charlotte Onland-Moret, Anne Andresson, Malin Sund, Elisabete Weiderpass, Kay Tee Khaw, Timothy J. Key, Ruth C. Travis, Melissa A. Merritt, Elio Riboli, Laure Dossus, Rudolf Kaaks

Research output: Contribution to journalArticle

Abstract

Introduction: The relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention. Methods: We analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched control subjects. Results: We found a significant positive association between higher circulating prolactin levels and risk of in situ breast cancer among all women [pre-and postmenopausal combined, ORlog2=1.35 (95% CI 1.04-1.76), Ptrend=0.03]. No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal status (Phet=0.98) or baseline HT use (Phet=0.20), although the observed association was more pronounced among postmenopausal women using HT compared to non-users (Ptrend=0.06 vs Ptrend=0.35). In subgroup analyses, the observed positive association was strongest in women diagnosed with in situ breast tumors trend=0.01 vs Ptrend=0.63; Phet=0.04) and among nulliparous women compared to parous women (Ptrend=0.03 vs Ptrend=0.15; Phet=0.07). Conclusions: Our data extends prior research linking prolactin and invasive breast cancer to the outcome of in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ breast cancer.

Original languageEnglish
Article number49
JournalBreast Cancer Research
Volume17
Issue number1
DOIs
Publication statusPublished - Mar 31 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: A case-control study'. Together they form a unique fingerprint.

  • Cite this

    Tikk, K., Sookthai, D., Fortner, R. T., Johnson, T., Rinaldi, S., Romieu, I., Tjønneland, A., Olsen, A., Overvad, K., Clavel-Chapelon, F., Baglietto, L., Boeing, H., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Masala, G., Krogh, V., Tumino, R., Ricceri, F., ... Kaaks, R. (2015). Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: A case-control study. Breast Cancer Research, 17(1), [49]. https://doi.org/10.1186/s13058-015-0563-6